U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C15H22N2O.ClH.2H2O
Molecular Weight 318.839
Optical Activity ( + / - )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PIQUINDONE HYDROCHLORIDE

SMILES

O.O.Cl.CCC1=C(C)NC2=C1C(=O)[C@@H]3CN(C)CC[C@H]3C2

InChI

InChIKey=GEAXXUIYNZBBLU-ZTALITPHSA-N
InChI=1S/C15H22N2O.ClH.2H2O/c1-4-11-9(2)16-13-7-10-5-6-17(3)8-12(10)15(18)14(11)13;;;/h10,12,16H,4-8H2,1-3H3;1H;2*1H2/t10-,12+;;;/m0.../s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H22N2O
Molecular Weight 246.348
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Piquindone is an antipsychotic pyrroloisoquinoline derivative that binds to dopamine D2 receptors. It is a potent D-2 antagonist. It has a low potential for extrapyramidal effects and tardive dyskinesia. Piquindone exhibited relatively weaker cataleptogenic and antistereotypic activity than haloperidol, and had minimal activity in a rat chronic stereotypy model of receptor supersensitivity. Piquindone almost as potent as haloperidol, with fewer or less intense extrapyramidal effects and low potential for tardive dyskinesia. Piquindone led to moderate but significant improvements in the positive symptoms of schizophrenia and to improvements in negative symptoms just below the level of statistical significance. Therapeutic efficacy of a piquindone antagonist in Tourette Syndrome can be achieved without production of disabling extrapyramidal-side effects.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacological options for the treatment of Tourette's disorder.
2001
A multiway 3D QSAR analysis of a series of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxybenzamides.
1998-01
The incorporation of butyrophenones and related compounds into a pharmacophore for dopamine D2 antagonists.
1997-08
Dopamine D2 receptor model explains binding affinity of neuroleptics: piquindone and its structure activity relationships.
1996-04
Optically active benzamides as predictive tools for mapping the dopamine D2 receptor.
1990-07-31
The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine.
1989-10-09
Structural requirements of Na+-dependent antidopaminergic agents: Tropapride, Piquindone, Zetidoline, and Metoclopramide. Comparison with Na+-independent ligands.
1989-03
Comparison of prolactin responses to D-1 and D-2 antagonists in rats: Ro 22-1319 is a potent D-2 antagonist.
1989-02-15
The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: two directions of D-1:D-2 interaction.
1989-02-07
Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
1989-01
Stereoelectronic study of zetidoline, a dopamine D2 receptor antagonist.
1989-01
Further evidence for two directions of D-1:D-2 dopamine receptor interaction revealed concurrently in distinct elements of typical and atypical behaviour: studies with the new enantioselective D-2 agonist LY 163502.
1989
Pharmacological activity profiles of dopamine D-1 and D-2 reception agonists and antagonists on striatal neuronal activity and the response to dexamphetamine in freely moving rats.
1989
Crystallographic, theoretical and molecular modelling studies on the conformations of the salicylamide, raclopride, a selective dopamine-D2 antagonist.
1987-10
The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia.
1987-10
The dopamine D-2 antagonist, Ro 22-1319, inhibits the persistent behavioral syndrome induced by iminodipropionitrile (IDPN) in mice.
1987-06
Effects of D2-dopaminergic receptor stimulation on male rat sexual behavior.
1987
The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors.
1986-09
Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist.
1986-07
Locomotor behaviors in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists.
1986-07
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:00:53 GMT 2025
Edited
by admin
on Mon Mar 31 18:00:53 GMT 2025
Record UNII
4IPC09W42Y
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PIQUINDONE HYDROCHLORIDE
MART.   USAN  
USAN  
Official Name English
RO-22-1319/003
Preferred Name English
PIQUINDONE HYDROCHLORIDE [MART.]
Common Name English
PIQUINDONE HCL
Common Name English
RO 22-1319/003
Code English
4H-PYRROLO(2,3-G)ISOQUINOLIN-4-ONE, 3-ETHYL-1,4A,5,6,7,8,8A,9-OCTAHYDRO-2,6-DIMETHYL-, MONOHYDROCHLORIDE, DIHYDRATE, TRANS-(±)-
Common Name English
4H-PYRROLO(2,3-G)ISOQUINOLIN-4-ONE, 3-ETHYL-1,4A,5,6,7,8,8A,9-OCTAHYDRO-2,6-DIMETHYL-, HYDROCHLORIDE, HYDRATE (1:1:2), (4AR,8AR)-REL-
Systematic Name English
PIQUINDONE HYDROCHLORIDE [USAN]
Common Name English
(±)-TRANS-3-ETHYL-1,4A,5,6,7,8,8A,9-OCTAHYDRO-2,6-DIMETHYL-4H-PYRROLO(2,3-G)ISOQUINOLIN-4-ONE MONOHYDROCHLORIDE DIHYDRATE
Common Name English
Code System Code Type Description
NCI_THESAURUS
C166760
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
EPA CompTox
DTXSID401003839
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
SMS_ID
300000055525
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
PUBCHEM
11954264
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
CAS
83784-19-4
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
ChEMBL
CHEMBL1192678
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
FDA UNII
4IPC09W42Y
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
USAN
U-45
Created by admin on Mon Mar 31 18:00:53 GMT 2025 , Edited by admin on Mon Mar 31 18:00:53 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY